Market Overview:
The global COPD medication market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of COPD, increasing awareness about COPD and its treatment, and technological advancements in the field of respiratory drugs. Based on type, the global COPD medication market is segmented into short-acting bronchodilators, corticosteroids, methylxanthines, long-acting bronchodilators, and combination drugs. The short-acting bronchodilator segment is expected to account for the largest share of the global COPD medication market in 2018. This can be attributed to their easy availability and low cost as compared to other types of respiratory drugs. Based on application, the hospital segment is expected to account for the largest share of the global COPD medication market in 2018. This can be attributed to rising incidence rates of hospitalization due with exacerbations caused by severe airflow obstruction among patients with chronic obstructive pulmonary disease (COPD). Geographically, North America dominates the global Copd Medication Market followed by Europe owing high prevalence rate for chronic obstructive pulmonary diseases (COPDs) cases across these regions respectively .
Product Definition:
COPD Medication is a type of bronchodilator that is used to help open up the airways in people who have COPD. This medication can help to make it easier for people to breathe, and can also help to reduce the symptoms of COPD.
Short-Acting Bronchodilator:
Short-Acting Bronchodilator Market Size, Share & Trends Analysis Report By Type (Nebulized, Inhaled), By Application (Acute Exacerbation of COPD, Chronic Obstructive Pulmonary Disease) And Segment Forecasts To 2024 -> The global short-acting bronchodilator market was valued at USD 765.9 million in 2015 and is expected to grow at a CAGR of XX% over the forecast period.
Corticosteroids:
Corticosteroids are a group of anti-inflammatory drugs that reduce inflammation by inhibiting the action of cytokines. Corticosteroid medication is used in COPD to reduce inflammation and prevent further damage to lung tissue.
Global Corticosteroids.
The global corticosteroids.
Application Insights:
Based on the application, the global COPD medication market is segmented into hospital, clinic, pharmacy and online pharmacy. The hospital was estimated as the largest application segment in 2017 owing to increasing prevalence of chronic respiratory diseases and growing geriatric population across the world. As per a WHO study published in 2018, around 300 million people aged 60 years or above were registered worldwide. This age group is at high risk of developing COPD due to smoking-related damages to their lungs over a lifetime. Thus rising number of patients suffering from COPD at hospitals results in larger share for this segment during epidemics like COVID-19 pandemic as there are more opportunities for patients suffering from COPD to seek medical treatment than others do when they are healthy enough not affected by such viruses/bacteria etc.
Regional Analysis:
North America dominated the global COPD medication market in 2017. This can be attributed to increasing prevalence of asthma, rising awareness about treatment options, and availability of advanced therapies for COPD. Moreover, high healthcare expenditure and presence of a large number of key players in this region are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to growing geriatric population coupled with an increase in lifestyle-related diseases such as cardiovascular disorders and respiratory problems including asthma among others that result into an increased demand for COPD medication. Furthermore, improving economic conditions will also contribute toward market development during the estimated time span.
Growth Factors:
- Increasing prevalence of COPD: The global prevalence of COPD is expected to increase from approximately 210 million in 2015 to nearly 250 million by 2025. This is due to the aging population and increasing exposure to risk factors such as smoking and air pollution.
- Growing demand for novel therapies: There is a growing demand for novel therapies that can improve patient outcomes and quality of life. This has led to the development of several new drugs in the market, such as tiotropium bromide (Spiriva), umeclidinium bromide (Incruse Ellipta), glycopyrronium bromide (Seebri Breezhaler), and indacaterol maleate (Arcapta Neohaler).
- Launch of generic versions: Several blockbuster drugs have lost their patent protection in recent years, leading to the launch of generic versions in the market. For instance, Advair Diskus (fluticasone propionate/salmeterol xinafoate) lost its patent protection in September 2017, which led to the launch of several generic versions by different manufacturers.
- Rising awareness about COPD: There is a growing awareness about COPD among patients and healthcare professionals alike. This has led to an increased demand for diagnosis and treatment services for this condition worldwide..
Scope Of The Report
Report Attributes
Report Details
Report Title
COPD Medication Market Research Report
By Type
Short-Acting Bronchodilator, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators, Combination Drugs
By Application
Hospital, Clinic, Pharmacy, Online Pharmacy
By Companies
Roche, Novartis, GSK, Teva, AstraZeneca, Boehringer Ingelheim, Nephron Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
124
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global COPD Medication Market Report Segments:
The global COPD Medication market is segmented on the basis of:
Types
Short-Acting Bronchodilator, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators, Combination Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- GSK
- Teva
- AstraZeneca
- Boehringer Ingelheim
- Nephron Pharmaceuticals
Highlights of The COPD Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Short-Acting Bronchodilator
- Corticosteroids
- Methylxanthines
- Long-Acting Bronchodilators
- Combination Drugs
- By Application:
- Hospital
- Clinic
- Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the COPD Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
COPD medication is a type of medication used to treat COPD. COPD medications help improve airflow in the lungs and can reduce the symptoms of COPD.
Some of the major players in the copd medication market are Roche, Novartis, GSK, Teva, AstraZeneca, Boehringer Ingelheim, Nephron Pharmaceuticals.
The copd medication market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 COPD Medication Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 COPD Medication Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 COPD Medication Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the COPD Medication Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global COPD Medication Market Size & Forecast, 2018-2028
4.5.1 COPD Medication Market Size and Y-o-Y Growth
4.5.2 COPD Medication Market Absolute $ Opportunity
Chapter 5 Global COPD Medication Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 COPD Medication Market Size Forecast by Type
5.2.1 Short-Acting Bronchodilator
5.2.2 Corticosteroids
5.2.3 Methylxanthines
5.2.4 Long-Acting Bronchodilators
5.2.5 Combination Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global COPD Medication Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 COPD Medication Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Pharmacy
6.2.4 Online Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global COPD Medication Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 COPD Medication Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America COPD Medication Analysis and Forecast
9.1 Introduction
9.2 North America COPD Medication Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America COPD Medication Market Size Forecast by Type
9.6.1 Short-Acting Bronchodilator
9.6.2 Corticosteroids
9.6.3 Methylxanthines
9.6.4 Long-Acting Bronchodilators
9.6.5 Combination Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America COPD Medication Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Pharmacy
9.10.4 Online Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe COPD Medication Analysis and Forecast
10.1 Introduction
10.2 Europe COPD Medication Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe COPD Medication Market Size Forecast by Type
10.6.1 Short-Acting Bronchodilator
10.6.2 Corticosteroids
10.6.3 Methylxanthines
10.6.4 Long-Acting Bronchodilators
10.6.5 Combination Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe COPD Medication Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Pharmacy
10.10.4 Online Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific COPD Medication Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific COPD Medication Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific COPD Medication Market Size Forecast by Type
11.6.1 Short-Acting Bronchodilator
11.6.2 Corticosteroids
11.6.3 Methylxanthines
11.6.4 Long-Acting Bronchodilators
11.6.5 Combination Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific COPD Medication Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Pharmacy
11.10.4 Online Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America COPD Medication Analysis and Forecast
12.1 Introduction
12.2 Latin America COPD Medication Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America COPD Medication Market Size Forecast by Type
12.6.1 Short-Acting Bronchodilator
12.6.2 Corticosteroids
12.6.3 Methylxanthines
12.6.4 Long-Acting Bronchodilators
12.6.5 Combination Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America COPD Medication Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Pharmacy
12.10.4 Online Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) COPD Medication Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) COPD Medication Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) COPD Medication Market Size Forecast by Type
13.6.1 Short-Acting Bronchodilator
13.6.2 Corticosteroids
13.6.3 Methylxanthines
13.6.4 Long-Acting Bronchodilators
13.6.5 Combination Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) COPD Medication Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Pharmacy
13.10.4 Online Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 COPD Medication Market: Competitive Dashboard
14.2 Global COPD Medication Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Novartis
14.3.3 GSK
14.3.4 Teva
14.3.5 AstraZeneca
14.3.6 Boehringer Ingelheim
14.3.7 Nephron Pharmaceuticals
